Biotech Values

[DewDiligence]

HZNP responds to FTC action:

https://www.businesswire.com/news/home/20230516005835/en

“…The FTC’s complaint impacts patients and is rooted in a theory about potential future “bundled” contracts with payors and not competitive overlap concerns. Horizon does not and has no plans to bundle any of its rare disease medicines. …We firmly believe in the benefits of this acquisition and intend to work with the court on a schedule that would allow the transaction to close by mid-December.”